By Elana Gotkine HealthDay ReporterTUESDAY, Oct. 24, 2023 -- Childhood cancer survivors who are carriers of cancer predisposing variants have increased subsequent malignant neoplasm-related late mortality, according to a study published in the October issue of The Lancet Oncology.Cheng Chen, from the Shanghai Jiao Tong University School of Medicine, and colleagues used data from two retrospective cohort studies -- St.

作者：Elana Gotkine HealthDay ReporterTUESDAY，2023年10月24日-根据10月份发表的“柳叶刀肿瘤学”杂志的一项研究，作为癌症易感变异体携带者的儿童癌症幸存者随后增加了与恶性肿瘤相关的晚期死亡率。Cheng Chen，来自上海交通大学医学院，及其同事使用了两项回顾性队列研究的数据-St。

Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor Study (CCSS) -- with prospective follow-up of patients alive for at least five years after diagnosis of childhood cancer with corresponding germline whole genome or whole exome sequencing data. Cancer predisposing variants affecting 60 genes that were linked to autosomal-dominant cancer-predisposition syndromes were characterized.A total of 12,469 participants were included: 4,402 from SJLIFE and 8,067 from CCSS.

Jude Lifetime Cohort（SJLIFE）和Childhood Cancer Survivor Study（CCSS）-在使用相应的种系全基因组或全外显子组测序数据诊断儿童癌症后，对存活至少五年的患者进行前瞻性随访。表征了影响与常染色体显性癌症易感综合征相关的60个基因的癌症易感变体。共有12469人参加：SJLIFE 4402人，CCSS 8067人。

The researchers found that 5.1 percent of the participants had cancer predisposing variants (6.7 and 4.3 percent in the SJLIFE and CCSS cohorts, respectively), which were significantly associated with increased severity of subsequent malignant neoplasms. Overall, there were 263 (2.1 percent) and 426 (3.4 percent) subsequent neoplasm-related and other-cause deaths, respectively.

研究人员发现，5.1%的参与者有癌症易感变异（SJLIFE和CCSS队列分别为6.7%和4.3%），这与随后恶性肿瘤的严重程度增加显着相关。总体而言，随后的肿瘤相关和其他原因死亡分别为263（2.1%）和426（3.4%）。

At 10 years after the first biospecimen collection, cumulative subsequent malignant neoplasm-related mortality was 3.7 and 6.9 percent in SJLIFE and CCSS carriers of cancer predisposing variants, respectively, versus 1.5 and 2.1 percent in noncarriers. The risk for subsequent neoplasm-related mortality was increased in association with carrying a cancer predisposing variant (subdistribution hazard ratios, 3.40 and 3.58 in SJLIFE and CCSS, respectively).'These results have crucial implications on the provision .

在首次收集生物样本后的10年中，癌症易感变体的SJLIFE和CCSS携带者的累积随后恶性肿瘤相关死亡率分别为3.7%和6.9%，而非携带者为1.5%和2.1%。与携带易患癌症的变异体（SJLIFE和CCSS的亚分布危险比分别为3.40和3.58）相关，随后肿瘤相关死亡的风险增加这些结果对该条款具有至关重要的意义。